Contract Development and Manufacturing Organization (CDMO)

Search documents
Lifecore Biomedical to Participate at 24th Annual Contract Pharma Contracting and Outsourcing Conference
Globenewswire· 2025-09-04 20:05
Core Insights - Lifecore Biomedical, Inc. will participate as a Gold Sponsor at the 24th Annual Contract Pharma Contracting and Outsourcing Conference on September 18-19, 2025, in New Brunswick, NJ, highlighting its commitment to the pharmaceutical outsourcing and contract manufacturing sector [1][2]. Company Overview - Lifecore is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products, including complex formulations [4]. - The company has over 40 years of experience in partnering with global and emerging biopharmaceutical and biotechnology companies across various therapeutic categories [4]. Growth Strategy - Lifecore's growth strategy focuses on three main areas: expanding existing customer relationships, advancing its late-stage development portfolio towards commercialization, and attracting new, high-value business [2][3]. - The participation in the Contract Pharma conference is part of the company's efforts to elevate awareness of its unique injectables development and manufacturing expertise [3]. Event Participation - At the conference, Lifecore will host meetings with existing and prospective customers and partners, aiming to strengthen its market presence and foster new business opportunities [3].
Quasar Medical Strengthens Global CDMO Platform with Acquisition of Nordson Medical's Galway and Tecate Facilities
Prnewswire· 2025-09-02 15:12
Core Insights - Quasar Medical has completed the acquisition of Nordson Corporation's design & development contract manufacturing businesses, enhancing its global CDMO platform and capabilities for medical device OEMs and innovators [1][3]. Company Expansion - The acquisition marks Quasar's evolution into a fully integrated CDMO, providing concept-to-commercialization solutions worldwide and expanding its workforce by nearly 200 employees [2][5]. - The addition of two FDA-registered, ISO 13485-certified facilities in Galway, Ireland, and Tecate, Mexico, strengthens Quasar's global presence and improves customer proximity [3][4]. Operational Enhancements - The Galway facility will serve as an innovation hub for design & development, focusing on extrusions, braiding, balloons, and complex catheters, while Tecate will provide cost-effective, high-volume manufacturing capabilities [3][5]. - The acquisition enhances Quasar's cleanroom footprint and technical expertise in various medical device technologies, leading to faster development and improved quality control [5][7]. Strategic Positioning - Quasar aims to position itself as a strategic partner to customers, offering a differentiated platform that combines upstream innovation and downstream scalability [4][6]. - The company will collaborate closely with Nordson to ensure a seamless transition for employees, customers, and suppliers [6].
Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025
Globenewswire· 2025-07-31 20:05
Company Overview - Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [3] Upcoming Financial Results - Lifecore will report its financial results for the fourth quarter and fiscal year 2025 on August 7, 2025, after market close [1] - A webcast hosted by Lifecore's senior management team will take place at 4:30 p.m. Eastern Time on the same day to discuss the results [1][2] Webcast Access - Investors can listen to the live webcast or access the archived version on Lifecore's Investor Events & Presentations page [2] - The archived version will be available for 30 days following the live event [2] Contact Information - Lifecore's investor relations contact is Stephanie Diaz from Vida Strategic Partners, reachable at 415-675-7401 [4] - Media inquiries can be directed to Tim Brons at 415-675-7402 [4] - Ryan D. Lake serves as the CFO of Lifecore Biomedical and can be contacted at 952-368-6244 [4]
OHA is Administrative Agent and Lead Left Arranger of Private Debt Financing Supporting Montagu’s Acquisition of Tyber Medical
Globenewswire· 2025-06-18 12:00
Core Insights - Oak Hill Advisors (OHA) acted as the Administrative Agent and Lead Left Arranger for the private senior debt financing for Montagu Private Equity's acquisition of Tyber Medical, a prominent orthopedic device manufacturer [1][2] - The acquisition will merge Tyber Medical with Montagu's existing portfolio companies, Resolve Surgical Technologies and Intech Medical, to form a scaled contract development and manufacturing organization (CDMO) [2] - OHA's extensive experience in the CDMO sector enabled it to efficiently assess the financing opportunity [3] Company Insights - Tyber Medical specializes in orthopedic devices, providing FDA-cleared and CE-marked implants for spinal, extremity, and trauma markets, with over 50 systems released since its inception in 2012 [7] - Montagu Private Equity focuses on mid-market investments, particularly in businesses with essential products in growing markets, managing €14 billion in assets [8][9] - OHA has approximately $95 billion in assets under management across various credit strategies as of March 31, 2025, emphasizing long-term partnerships and customized credit solutions [5][6]